Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

Lipid Nanoparticle-Mediated Co-Delivery of IL-33 mRNA and STING Agonist Modulates the Breast Cancer Microenvironment and Potentiates Immunotherapy

May 13, 2026

[Journal of Nanobiotechnology] Investigators provided a basis for further development of combination immunotherapy strategies for poorly immunogenic breast cancer, including strategies to improve responses to checkpoint blockade.

Estrogen-Mediated NF-κB Blockade Enables Breast Cancer Sensitivity to Oncolytic VSV Virotherapy

May 13, 2026

[Molecular Therapy] With the goal of enhancing oncolytic virotherapy independently of E2, scientists designed a treatment strategy that combines oncolytic Vesicular stomatitis virus with the NF-κB inhibitors IKK16 and Sulfasalazine and found that both drugs improved virus replication in TNBC cell lines and patient samples.

Regulation of Antiviral and Antitumor Immunity by the Pseudogene in Human Cancers

May 13, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Researchers showed that BRCA1P1 expression varies across multiple cancer cell types, with no significant association with BRCA1 or BRCA2 somatic mutations in breast and ovarian tumors.

Sapu Nano Announces First Patient Dosed in Phase Ib Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus

May 13, 2026

[Sapu Nano (Globe Newswire)] First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC.

Runx1 and Runx2 Act in Concert to Suppress Wnt/β-Catenin-Driven Mammary Tumourigenesis

May 8, 2026

[British Journal of Cancer] Scientists investigate the putative tumour suppressor role of Runx in genetic mouse models of breast cancer. Combined Runx1 and Runx2 loss accelerates disease progression.

HER2-Driven Mammary Tumorigenesis Enhances Bioenergetics Despite Reductions in Mitochondrial Content

May 8, 2026

[Elife] Scientists assessed the bulk tumor and mitochondrial metabolic phenotype in murine HER2-driven mammary cancer tumors and benign mammary tissue.

Pervasive Enhanced Transcription in Inflammatory Breast Cancer Tumors and PBMCs Impacts RNA Splicing and Intronic RNAs in Plasma

May 5, 2026

[Science Advances] By mapping reads to genome and transcriptome reference sequences and quantitating intron-to-exon read depth ratios, scientists developed methods for parallel analysis of transcriptional and posttranscriptional gene regulation.

Microfluidic Assembly of NIR-II AIE Nanoparticles for Enhanced Photothermal Ablation of Breast Tumors

May 5, 2026

[Advanced Healthcare Materials] Scientists reported an NIR-II emissive aggregation-induced emission (AIE) small molecule that can be rapidly assembled into monodisperse nanoparticles using a microfluidic strategy that ensures reproducible control over particle size and uniformity.

The Neuroimmune Axis in Breast Cancer: From Mechanistic Insights to Clinical Applications

May 5, 2026

[BMC Medicine] The authors summarize the major mechanisms underlying neuroimmune regulation in breast cancer and discuss emerging therapeutic strategies, including repurposing of neuroactive agents, breast-targeted drug delivery systems, and neural stimulation combined with immune checkpoint blockade.

NCOR2 Represses MHC Class I Molecule Expression to Drive Metastatic Progression of Breast Cancer

May 5, 2026

[Nature Communications] Researchers showed that nuclear corepressor 2 (NCOR2) is an epigenetic regulator of MHC class I molecule presentation on breast tumor cells. Patients with TNBC that express high levels of NCOR2 also exhibit reduced metastasis-free survival and decreased MHC class I expression.

Crosstalk between Integrin Signaling and NAD⁺ Biosynthetic Pathways Promotes Glycolysis, Proliferation, Survival, and Tumor Growth in Triple-Negative Breast Cancer

April 30, 2026

[Oncogene] Researchers investigated how integrin-dependent signaling pathways regulate tumor metabolism and therapeutic vulnerability in TNBC.

Kaur Receives $535,000 NIH Grant for Breakthrough Breast Cancer Treatment

April 30, 2026

[Chapman University] Dr. Kamaljit Kaur has received a $535,000 National Cancer Institute award from the National Institutes of Health..Dr. Kaur and her research team are developing novel peptide-drug conjugates designed to recognize and bind to EGFR, a protein found in elevated levels on the surface of TNBC cells.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.